Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

Objectives To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence.Design A dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services.Setting The study was conduct...

Full description

Bibliographic Details
Main Authors: Adrian Dunlop, Andrew Carr, Nicholas Lintzeris, Zhixin Liu, Nadine Ezard, Raimondo Bruno, Brendan Clifford, Krista J Siefried
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/5/e044696.full

Internet

https://bmjopen.bmj.com/content/11/5/e044696.full

Similar Items